logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (6)
  • CSV
  • BibTeX
  • EndNote
  • All Results (6)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Letter

Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes

Campbell JR, Chan ED, Anderson LF, Bonnet M, Brode SK, 
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
et al.
2023-04-01 • International Journal of Tuberculosis and Lung Disease
2023-04-01 • International Journal of Tuberculosis and Lung Disease

Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A,  et al.
2020-03-20 • European Respiratory Journal
2020-03-20 • European Respiratory Journal
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a sta...

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa a retrospective cohort study

Ndjeka N, Campbell JR, Meintjes GA, Maartens G, Schaaf HS,  et al.
2022-05-02 • Lancet Infectious Diseases
2022-05-02 • Lancet Infectious Diseases
BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...

Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis

Bisson GP, Bastos ML, Campbell JR, Bang D, Brust JCM,  et al.
2020-08-08 • Lancet
2020-08-08 • Lancet
BACKGROUND
HIV-infection is associated with increased mortality during multidrug-resistant tuberculosis treatment, but the extent to which the use of antiretroviral therapy (ART) and...

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A,  et al.
2020-03-17 • Lancet Respiratory Medicine
2020-03-17 • Lancet Respiratory Medicine

BACKGROUND

Tre...